Is there thrombin-activatable fibrinolysis inhibitor in saliva?

被引:0
|
作者
Chopra, S. [1 ]
Friman, E. [2 ]
Krueger, C. W. [1 ,3 ]
Antovic, J. P. [4 ,5 ]
Naimi-Akbar, A. [1 ,3 ,6 ]
机构
[1] Karolinska Inst, Dept Dent Med, Huddinge, Sweden
[2] Karolinska Univ Hosp, Dept Oral & Maxillofacial Surg, Stockholm, Sweden
[3] Folktandvarden Stockholm AB, Eastmaninst, Dept Oral & Maxillofacial Surg, Stockholm, Sweden
[4] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden
[5] Karolinska Univ Hosp, Coagulat, Clin Chem, Stockholm, Sweden
[6] Malmo Univ, Fac Odontol, Hlth Technol Assessment Odontol HTAO, Malmo, Sweden
来源
关键词
Saliva; TAFI; Blood Coagulation; Fibrinolysis; TAFI; PLASMINOGEN; COAGULATION;
D O I
10.1016/j.bjoms.2020.05.018
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
The purpose of this study was to identify thrombin-activatable fibrinolysis inhibitor (TAFI) in saliva and to investigate the correlation between TAFI levels in saliva and plasma. Subjects included were healthy adults without diseases or medication that could affect coagulation. Samples of stimulated saliva and blood samples were obtained from 33 subjects. Levels of TAFI in saliva and plasma were analysed. The association between levels of TAFI in saliva and plasma was calculated using linear regression. Low levels of TAFIa/TAFIai were found in most saliva samples but only one sample had levels that were above the lower limit of detection of the assay used. TAFI (proenzyme) was not found in saliva, so no correlations could be calculated. In this study there was no indication that there is TAFI present in secreted saliva. Either TAFIa/TAFIai in saliva were much lower than in plasma and under the detection limit of the assay used, or there was no TAFIa/TAFIai in the saliva tested. (c) 2020 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:E33 / E37
页数:5
相关论文
共 50 条
  • [1] Thrombin-activatable fibrinolysis inhibitor
    Marx, PF
    CURRENT MEDICINAL CHEMISTRY, 2004, 11 (17) : 2335 - 2348
  • [2] The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor
    Verkleij, C. J. N.
    Nieuwdorp, M.
    Gerdes, V. E. A.
    Morgelin, M.
    Meijers, J. C. M.
    Marx, P. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 392 - 392
  • [3] Characterization of mouse thrombin-activatable fibrinolysis inhibitor
    Marx, PF
    Wagenaar, GTM
    Reijerkerk, A
    Tiekstra, MJ
    van Rossum, AGSH
    Gebbink, MFBG
    Meijers, JCM
    THROMBOSIS AND HAEMOSTASIS, 2000, 83 (02) : 297 - 303
  • [4] Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia
    Verkleij, Chantal J. N.
    Stuijver, Danka J. F.
    van Zaane, Bregje
    Squizzato, Alessandro
    Brandjes, Dees P. M.
    Buller, Harry R.
    Meijers, Joost C. M.
    Gerdes, Victor E. A.
    THROMBOSIS AND HAEMOSTASIS, 2013, 109 (02) : 214 - 220
  • [5] The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor
    Verkleij, Chantal J. N.
    Nieuwdorp, Max
    Gerdes, Victor E. A.
    Morgelin, Matthias
    Meijers, Joost C. M.
    Marx, Pauline F.
    THROMBOSIS AND HAEMOSTASIS, 2009, 102 (03) : 460 - 468
  • [6] Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity
    Zhou, X.
    Weeks, S. D.
    Ameloot, P.
    Callewaert, N.
    Strelkov, S. V.
    Declerck, P. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (08) : 1629 - 1638
  • [7] Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice
    Nagashima, M
    Yin, ZF
    Broze, GJ
    Morser, J
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2002, 7 : D556 - D568
  • [8] Recent Developments in Thrombin-Activatable Fibrinolysis Inhibitor Research
    Marx, Pauline F.
    Verkleij, Chantal J. N.
    Seron, Mercedes Valls
    Meijers, Joost C. M.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2009, 9 (10) : 1165 - 1173
  • [9] Thrombin-Activatable Fibrinolysis Inhibitor in Breast Cancer Patients
    Kaftan, O.
    Kasapoglu, B.
    Koroglu, M.
    Kosar, A.
    Yalcin, S. K.
    MEDICAL PRINCIPLES AND PRACTICE, 2011, 20 (04) : 332 - 335
  • [10] The Role of Thrombin-Activatable Fibrinolysis Inhibitor in the Pathophysiology of Hemostasis
    Dubis, Joanna
    Witkiewicz, Wojciech
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2010, 19 (03): : 379 - 387